Skip to main content

Table 1 Demographic and clinical data of patients included in the study

From: Penicillin and cephalosporin cross-reactivity: role of side chain and synthetic cefadroxil epitopes

Pat Group Sex Age Drug Epi Reaction IDR (min) IRS (d)
1 A M 55 AX-CLV 1 Anaphylaxis 60 180
2 B M 44 AX-CLV 1 Anaphylaxis 20 60
3 A M 46 AX 1 Anaphylaxis 30 30
4 B M 55 AX 1 Urticaria 30 300
5 A M 62 AX-CLV 1 Anaphylaxis 60 90
6 B F 45 AX-CLV 1 Anaphylaxis 10 30
7 B M 24 AX 1 Anaphylaxis 10 30
8 B F 45 AX 1 Anaphylaxis 20 90
9 A M 47 AX 2 Urticaria
Anaphylaxis
40
10
477
365
10 A F 46 AX-CLV 1 Anaphylaxis 30 120
11 A M 43 AX-CLV 1 Anaphylaxis 45 60
12 B F 40 AX/AX-CLV 2 Urticaria
Anaphylaxis
30
5
112
109
13 A F 16 AX-CLV 1 Urticaria 60 30
14 A M 27 AX-CLV 1 Anaphylactic shock 5 21
15 A M 66 AX 1 Anaphylaxis 60 365
16 B M 44 AX 1 Anaphylaxis 10 365
17 A F 50 AX-CLV 1 Anaphylaxis 15 30
18 A M 44 AX-CLV 1 Anaphylaxis 10 280
19 A M 25 AX-CLV 1 Urticaria 60 120
20 B F 33 AX-CLV 1 Anaphylaxis 15 6
21 B F 36 AX-CLV 1 Anaphylaxis 30 60
22 A M 30 AX 1 Anaphylaxis 5 20
23 B M 45 AX-CLV 1 Anaphylactic shock 5 30
24 A M 30 AX-CLV 1 Anaphylaxis 30 210
25 B M 57 AX-CLV 1 Anaphylaxis 5 60
26 A M 49 AX 1 Anaphylaxis 10 120
27 A F 39 AX 1 Urticaria 40 40
28 A F 39 AX-CLV 1 Urticaria 60 95
29 A F 21 AX-CLV 1 Anaphylaxis 15 230
30 A M 46 AX-CLV 1 Anaphylaxis 2 137
31 B M 49 AX 1 Anaphylaxis 5 180
32 B F 37 AX-CLV 1 Anaphylaxis 20 30
33 A F 57 AX 1 Anaphylaxis 30 90
34 B M 26 AX 1 Anaphylaxis 20 10
35 B M 48 AX-CLV 1 Anaphylaxis 60 146
36 A M 23 AX-CLV 1 Anaphylaxis 50 60
37 B F 42 AX 1 Anaphylaxis 5 120
38 B M 57 AX-CLV 1 Anaphylaxis 30 28
39 B M 30 AX-CLV 1 Urticaria 10 730
40 A F 37 AX-CLV 1 Anaphylaxis 5 30
41 A F 14 AX-CLV 1 Anaphylaxis 10 90
42 A M 44 AX 1 Urticaria 30 120
43 A M 28 AX 2 Anaphylaxis
Anaphylaxis
20
25
230
180
44 A M 63 AX-CLV 1 Anaphylaxis 10 30
45 A M 51 AX 1 Urticaria 60 30
46 A M 35 AX 1 Urticaria 30 90
47 A M 32 AX 1 Anaphylaxis 45 180
48 A M 53 AX 1 Anaphylaxis 30 90
49 A M 44 AX 1 Urticaria 45 120
50 A F 38 AX-CLV 1 Anaphylaxis 10 30
51 A M 54 AX-CLV 1 Anaphylactic shock 5 90
52 A F 62 AX-CLV 1 Urticaria 60 210
53 B M 49 AX-CLV 1 Anaphylaxis 30 120
54 A F 44 AX 1 Anaphylactic shock 5 240
  1. Patients were classified into Group A (Good tolerance to cefadroxil) or Group B (Cross-reactivity with cefadroxil)
  2. Pat, Patients; M, Male; F, Female; AX-CLV, Amoxicillin-clavulanic; AX, Amoxicillin; Epi, Number of episodes; IDR (min), Interval drug administration and development of symptoms in minutes; IRS (d), Interval last reaction and allergological study in days
\